Accelerated Chemo Immuno Therapy Against Cancer_Skattefunn002

Offentlig prosjektsammendrag

Malignant solid tumours are challenging to treat due to their poor and irregular vascularization which causes a reduction in drug penetration. Therefore, effective treatment requires more chemotherapy sessions leading to more prolonged exposure to the highly toxic drugs, producing severe side effects. Enhancing drug penetration and accelerated uptake in tumoral tissues would significantly improve treatment success rates and patients' quality of life. Evidence, growing in numbers, indicates on-site immunotherapies are effective in multiple cancer types, and therefore, the combination of immunotherapy with nano-careers appears beneficial in a broad range of tumours. The choice of therapeutic agents and the timing of these combinations is critical, and therefore further computational and wet-lab experimental research is required to develop the radically innovative technology. ACITAC have the vision to develop (an innovative platform technology derived) nanoformulations embedding the chemotherapeutic drug and surface-grafted with two other different classes of active pharmaceutical ingredients that will allow accelerated and safe delivery of the chemotherapeutic to cancer cells target-specifically within tumours. We propose to use unique molecules in optimized concentration to improve radically the penetration of nanoformulations within tumours by using the tumour microenvironment conditions. These nanoformulations will be actively targeted using monoclonal antibodies (mAbs) for the controlled release of drugs, thus improving the efficacy and safety of the treatment. Moreover, being targeted the mAbs will enhance anti-tumour immune cell populations through antigen-specific immune responses. Therefore, this novel nano-immuno-chemotherapy is expected to accelerate the API uptake and immunotherapeutic mechanisms to kill the cancer cells in minimum time through dual-action.